Skip to main content
Top
Published in: Supportive Care in Cancer 6/2014

01-06-2014 | Original Article

Quality of life in long-term survivors following treatment for Hodgkin's disease during childhood and adolescence in the German multicentre studies between 1978 and 2002

Authors: Gabriele Calaminus, Wolfgang Dörffel, Katja Baust, Carmen Teske, Marianne Riepenhausen, Jürgen Brämswig, Hans-Henning Flechtner, Susanne Singer, Andreas Hinz, Günther Schellong

Published in: Supportive Care in Cancer | Issue 6/2014

Login to get access

Abstract

Purpose

The purpose of this study was to cross-sectionally assess quality of life (QoL) in survivors of childhood Hodgkin's disease (HD) in a cohort treated for HD in the successive German–Austrian therapy studies HD-78, HD-82, HD-85, HD-87, HD-90, HD-95, respectively, in accordance with the HD-Interval-Treatment recommendation between 1978 and 2002.

Patients and methods

Data from QoL questionnaires were provided by 1,202 (66 %) of 1,819 invited survivors. These included the EORTC QLQ-C30 and socio-demographic variables. Data of a homogenous sub-sample (n = 725) defined by age (21–41 years) and event- free-survival (no progress, relapse or secondary malignancies) were compared to an age-adjusted German reference sample (n = 659).

Results

While the global and physical QoL scores were comparable to those of the general population, survivors' mean scores were more than 10 points lower on the EORTC QLQ-C30 scales “Emotional” and “Social Functioning”. On the symptom scales, higher mean scores, exceeding 10 points, were obtained for the scales “Fatigue” and “Sleep”. In general, there was a gender effect showing lower functioning and higher symptom levels in women, most prominently in the group of young women (21–25 years). The results within the group of HD survivors could not be associated with the time since treatment, the age of HD survivors at diagnosis or the extent of therapy burden.

Conclusion

Clinicians engaged in follow-up care should be sensitive to aspects of fatigue and related (emotional) symptoms in HD childhood cancer survivors and encourage their patients to seek further support if needed.
Literature
1.
go back to reference Heutte N, Flechtner HH, Mounier N, Mellink WA, for the EORTC GELA H8 Trial Group et al (2009) Quality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTC GELA H8 randomised controlled trial. Lancet Oncol 10:1160–1170PubMedCrossRef Heutte N, Flechtner HH, Mounier N, Mellink WA, for the EORTC GELA H8 Trial Group et al (2009) Quality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTC GELA H8 randomised controlled trial. Lancet Oncol 10:1160–1170PubMedCrossRef
2.
go back to reference Rüffer JU, Flechtner H, Tralls P, for the German Hodgkin Lymphoma Study Group et al (2003) Fatigue in long-term survivors of Hodgkin's lymphoma: a report from the German Hodgkin Lymphoma Study Group (GHSG). Eur J Cancer 39:2179–2186PubMedCrossRef Rüffer JU, Flechtner H, Tralls P, for the German Hodgkin Lymphoma Study Group et al (2003) Fatigue in long-term survivors of Hodgkin's lymphoma: a report from the German Hodgkin Lymphoma Study Group (GHSG). Eur J Cancer 39:2179–2186PubMedCrossRef
3.
go back to reference Flechtner H, Rüffer JU, Henry-Amar M et al (1998) Quality of life assessment in Hodgkin's disease: a new comprehensive approach: first experiences from the EORTC/GELA and GHSG trials. EORTC Lymphoma Cooperative Group. Groupe D’Etude des Lymphomes de L’Adulte and German Hodgkin Study Group. Ann Oncol 9(Suppl 5):147–154CrossRef Flechtner H, Rüffer JU, Henry-Amar M et al (1998) Quality of life assessment in Hodgkin's disease: a new comprehensive approach: first experiences from the EORTC/GELA and GHSG trials. EORTC Lymphoma Cooperative Group. Groupe D’Etude des Lymphomes de L’Adulte and German Hodgkin Study Group. Ann Oncol 9(Suppl 5):147–154CrossRef
4.
go back to reference Dörffel W, Körholz D (2010) Hodgkin's lymphoma. In: Estlin EJ, Gilbertson RJ, Wynn RF (eds) Pediatric hematology and oncology. Wiley-Blackwell, New York, pp 130–148CrossRef Dörffel W, Körholz D (2010) Hodgkin's lymphoma. In: Estlin EJ, Gilbertson RJ, Wynn RF (eds) Pediatric hematology and oncology. Wiley-Blackwell, New York, pp 130–148CrossRef
5.
go back to reference Stanton AL (2006) Psychosocial concerns and interventions for cancer survivors. J Clin Oncol 24:5132–5137PubMedCrossRef Stanton AL (2006) Psychosocial concerns and interventions for cancer survivors. J Clin Oncol 24:5132–5137PubMedCrossRef
6.
go back to reference Cantrell MA (2011) A narrative review summarizing the state of the evidence on the health-related quality of life among childhood cancer survivors. J Pediatr Oncol Nurs 28:75–82PubMedCrossRef Cantrell MA (2011) A narrative review summarizing the state of the evidence on the health-related quality of life among childhood cancer survivors. J Pediatr Oncol Nurs 28:75–82PubMedCrossRef
7.
go back to reference McDougall J, Tsonis M (2009) Quality of life in survivors of childhood cancer: a systematic review of the literature (2001–2008). Support Care Cancer 17:1231–1246PubMedCrossRef McDougall J, Tsonis M (2009) Quality of life in survivors of childhood cancer: a systematic review of the literature (2001–2008). Support Care Cancer 17:1231–1246PubMedCrossRef
8.
go back to reference Zeltzer LK, Recklitis C, Buchbinder D, Zebrack B, Casillas J, Tsao JC, Lu Q, Krull K (2009) Psychological status in childhood cancer survivors: a report from the Childhood Cancer Survivor Study. J Clin Oncol 27:2396–2404PubMedCentralPubMedCrossRef Zeltzer LK, Recklitis C, Buchbinder D, Zebrack B, Casillas J, Tsao JC, Lu Q, Krull K (2009) Psychological status in childhood cancer survivors: a report from the Childhood Cancer Survivor Study. J Clin Oncol 27:2396–2404PubMedCentralPubMedCrossRef
9.
go back to reference Lund LW, Schmiegelow K, Rechnitzer C, Johansen C (2011) A systematic review of studies on psychosocial late effects of childhood cancer: structures of society and methodological pitfalls may challenge the conclusions. Pediatr Blood Cancer 56:532–543PubMedCrossRef Lund LW, Schmiegelow K, Rechnitzer C, Johansen C (2011) A systematic review of studies on psychosocial late effects of childhood cancer: structures of society and methodological pitfalls may challenge the conclusions. Pediatr Blood Cancer 56:532–543PubMedCrossRef
10.
go back to reference Zeltzer LK, Lu Q, Leisenring W, Tsao JC, Recklitis C, Armstrong G, Mertens AC, Robison LL, Ness KK (2008) Psychosocial outcomes and health-related quality of life in adult childhood cancer survivors: a report from the childhood cancer survivor study. Cancer Epidemiol Biomarkers Prev 17:435–446PubMedCrossRef Zeltzer LK, Lu Q, Leisenring W, Tsao JC, Recklitis C, Armstrong G, Mertens AC, Robison LL, Ness KK (2008) Psychosocial outcomes and health-related quality of life in adult childhood cancer survivors: a report from the childhood cancer survivor study. Cancer Epidemiol Biomarkers Prev 17:435–446PubMedCrossRef
11.
go back to reference Maunsell E, Pogany L, Barrera M et al (2006) Quality of life among long-term adolescent and adult survivors of childhood cancer. J Clin Oncol 24:2527–2535PubMedCrossRef Maunsell E, Pogany L, Barrera M et al (2006) Quality of life among long-term adolescent and adult survivors of childhood cancer. J Clin Oncol 24:2527–2535PubMedCrossRef
12.
go back to reference Ishida Y, Honda M, Kamibeppu K et al (2011) Social outcomes and quality of life of childhood cancer survivors in Japan: a cross-sectional study on marriage, education, employment and health-related QOL (SF-36). Int J Hematol 93:633–644PubMedCrossRef Ishida Y, Honda M, Kamibeppu K et al (2011) Social outcomes and quality of life of childhood cancer survivors in Japan: a cross-sectional study on marriage, education, employment and health-related QOL (SF-36). Int J Hematol 93:633–644PubMedCrossRef
13.
go back to reference Arden-Close E, Pacey A, Eiser C (2010) Health-related quality of life in survivors of lymphoma: a systematic review and methodological critique. Leuk Lymphoma 51:628–640PubMedCrossRef Arden-Close E, Pacey A, Eiser C (2010) Health-related quality of life in survivors of lymphoma: a systematic review and methodological critique. Leuk Lymphoma 51:628–640PubMedCrossRef
14.
go back to reference Mulrooney DA, Ness KK, Neglia JP et al (2008) Fatigue and sleep disturbance in adult survivors of childhood cancer: a report from the Childhood Cancer Survivor Study (CCSS). Sleep 31:271–281PubMedCentralPubMed Mulrooney DA, Ness KK, Neglia JP et al (2008) Fatigue and sleep disturbance in adult survivors of childhood cancer: a report from the Childhood Cancer Survivor Study (CCSS). Sleep 31:271–281PubMedCentralPubMed
15.
go back to reference King MT (1996) The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30. Qual Life Res 5:555–567PubMedCrossRef King MT (1996) The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30. Qual Life Res 5:555–567PubMedCrossRef
16.
go back to reference Brämswig JH, Hörnig-Franz I, Riepenhausen M et al (1990) The challenge of pediatric Hodgkin's disease: where is the balance between cure and long-term toxicity? A report of the West German multicenter studies DAL-HD-78, DAL-HD-82 and DAL-HD-85. Leuk Lymphoma 3:183–193CrossRef Brämswig JH, Hörnig-Franz I, Riepenhausen M et al (1990) The challenge of pediatric Hodgkin's disease: where is the balance between cure and long-term toxicity? A report of the West German multicenter studies DAL-HD-78, DAL-HD-82 and DAL-HD-85. Leuk Lymphoma 3:183–193CrossRef
17.
go back to reference Schellong G, Hörnig-Franz I, Rath B et al (1994) Reducing radiation dosage to 20–30 Gy in combined chemo-/radiotherapy of Hodgkin's disease in childhood. A report of the cooperative DAL-HD-87 therapy study. Klin Padiatr 206:253–262PubMedCrossRef Schellong G, Hörnig-Franz I, Rath B et al (1994) Reducing radiation dosage to 20–30 Gy in combined chemo-/radiotherapy of Hodgkin's disease in childhood. A report of the cooperative DAL-HD-87 therapy study. Klin Padiatr 206:253–262PubMedCrossRef
18.
go back to reference Schellong G (1996) Treatment of children and adolescents with Hodgkin's disease: the experience of the German–Austrian Paediatric Study Group. Baillieres Clin Haematol 9:619–634PubMedCrossRef Schellong G (1996) Treatment of children and adolescents with Hodgkin's disease: the experience of the German–Austrian Paediatric Study Group. Baillieres Clin Haematol 9:619–634PubMedCrossRef
19.
go back to reference Schellong G, Potter R, Brämswig J et al (1999) High cure rates and reduced long-term toxicity in pediatric Hodgkin's disease: the German–Austrian multicenter trial DAL-HD-90. The German–Austrian Pediatric Hodgkin's Disease Study Group. J Clin Oncol 17:3736–3744PubMed Schellong G, Potter R, Brämswig J et al (1999) High cure rates and reduced long-term toxicity in pediatric Hodgkin's disease: the German–Austrian multicenter trial DAL-HD-90. The German–Austrian Pediatric Hodgkin's Disease Study Group. J Clin Oncol 17:3736–3744PubMed
20.
go back to reference Dörffel W, Lüders H, Rühl U et al (2003) Preliminary results of the multicenter trial GPOH-HD 95 for the treatment of Hodgkin's disease in children and adolescents: analysis and outlook. Klin Padiatr 215:139–145PubMedCrossRef Dörffel W, Lüders H, Rühl U et al (2003) Preliminary results of the multicenter trial GPOH-HD 95 for the treatment of Hodgkin's disease in children and adolescents: analysis and outlook. Klin Padiatr 215:139–145PubMedCrossRef
21.
go back to reference Lüders H, Marciniak H, Rühl U et al (2011) Importance of prospective treatment planning by a reference center in pediatric Hodgkin lymphoma—a retrospective assessment of the HD-interval period following the trial GPOH-HD 95. Pediatr Blood Cancer 880 (abstr I-ISCAYAHL) Lüders H, Marciniak H, Rühl U et al (2011) Importance of prospective treatment planning by a reference center in pediatric Hodgkin lymphoma—a retrospective assessment of the HD-interval period following the trial GPOH-HD 95. Pediatr Blood Cancer 880 (abstr I-ISCAYAHL)
22.
go back to reference Brämswig JH, Heimes U, Heiermann E et al (1990) The effects of different cumulative doses of chemotherapy on testicular function. Results in 75 patients treated for Hodgkin's disease during childhood or adolescence. Cancer 65:1298–1302PubMedCrossRef Brämswig JH, Heimes U, Heiermann E et al (1990) The effects of different cumulative doses of chemotherapy on testicular function. Results in 75 patients treated for Hodgkin's disease during childhood or adolescence. Cancer 65:1298–1302PubMedCrossRef
23.
go back to reference Schellong G, Riepenhausen M, Creutzig U et al (1997) Low risk of secondary leukemias after chemotherapy without mechlorethamine in childhood Hodgkin's disease. German–Austrian Pediatric Hodgkin's Disease Group. J Clin Oncol 15:2247–2253PubMed Schellong G, Riepenhausen M, Creutzig U et al (1997) Low risk of secondary leukemias after chemotherapy without mechlorethamine in childhood Hodgkin's disease. German–Austrian Pediatric Hodgkin's Disease Group. J Clin Oncol 15:2247–2253PubMed
24.
go back to reference Schellong G, Riepenhausen M (2004) Late effects after therapy of Hodgkin's disease: update 2003/04 on overwhelming post-splenectomy infections and secondary malignancies. Klin Padiatr 216:364–369PubMedCrossRef Schellong G, Riepenhausen M (2004) Late effects after therapy of Hodgkin's disease: update 2003/04 on overwhelming post-splenectomy infections and secondary malignancies. Klin Padiatr 216:364–369PubMedCrossRef
25.
go back to reference Dörffel W, Riepenhausen M, Ludwig WD, Schellong G (2010) Langzeitfolgen nach Therapie eines Hodgkin-Lymphoms bei Kindern und Jugendlichen. J Onkologie 9:449–456 Dörffel W, Riepenhausen M, Ludwig WD, Schellong G (2010) Langzeitfolgen nach Therapie eines Hodgkin-Lymphoms bei Kindern und Jugendlichen. J Onkologie 9:449–456
26.
go back to reference Schellong G, Riepenhausen M, Bruch C et al (2010) Late valvular and other cardiac diseases after different doses of mediastinal radiotherapy for Hodgkin disease in children and adolescents: report from the longitudinal GPOH follow-up project of the German-Austrian DAL-HD studies. Pediatr Blood Cancer 55:1145–1152PubMedCrossRef Schellong G, Riepenhausen M, Bruch C et al (2010) Late valvular and other cardiac diseases after different doses of mediastinal radiotherapy for Hodgkin disease in children and adolescents: report from the longitudinal GPOH follow-up project of the German-Austrian DAL-HD studies. Pediatr Blood Cancer 55:1145–1152PubMedCrossRef
27.
go back to reference Aaronson NK, Ahmedzai S, Bergman B et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376PubMedCrossRef Aaronson NK, Ahmedzai S, Bergman B et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376PubMedCrossRef
28.
go back to reference Hjermstad MJ, Fayers PM, Bjordal K, Kaasa S (1998) Using reference data on quality of life—the importance of adjusting for age and gender, exemplified by the EORTC QLQ-C30 (+3). Eur J Cancer 34:1381–1389PubMedCrossRef Hjermstad MJ, Fayers PM, Bjordal K, Kaasa S (1998) Using reference data on quality of life—the importance of adjusting for age and gender, exemplified by the EORTC QLQ-C30 (+3). Eur J Cancer 34:1381–1389PubMedCrossRef
29.
go back to reference Fayers P, Aaronson N, Bjordal K, Groenvold M, Curran D, Bottomley A (2001) EORTC QLQ-C30 scoring manual, 3rd edn. EORTC, Brüssel Fayers P, Aaronson N, Bjordal K, Groenvold M, Curran D, Bottomley A (2001) EORTC QLQ-C30 scoring manual, 3rd edn. EORTC, Brüssel
30.
go back to reference Schwarz R, Hinz A (2001) Reference data for the quality of life questionnaire EORTC QLQ-C30 in the general German population. Eur J Cancer 37:1345–1351PubMedCrossRef Schwarz R, Hinz A (2001) Reference data for the quality of life questionnaire EORTC QLQ-C30 in the general German population. Eur J Cancer 37:1345–1351PubMedCrossRef
31.
go back to reference Rost D (2005) Interpretation und Bewertung pädagogisch-psychologischer Studien. Beltz, Weinheim Rost D (2005) Interpretation und Bewertung pädagogisch-psychologischer Studien. Beltz, Weinheim
32.
go back to reference Singer S, Kuhnt S, Zwerenz R et al (2011) Age- and sex-standardised prevalence rates of fatigue in a large hospital-based sample of cancer patients. Br J Cancer 105(3):445–451PubMedCentralPubMedCrossRef Singer S, Kuhnt S, Zwerenz R et al (2011) Age- and sex-standardised prevalence rates of fatigue in a large hospital-based sample of cancer patients. Br J Cancer 105(3):445–451PubMedCentralPubMedCrossRef
33.
go back to reference Dieluweit U, Debatin KM, Grabow D et al (2010) Social outcomes of long-term survivors of adolescent cancer. Psychooncology 19:1277–1284PubMedCrossRef Dieluweit U, Debatin KM, Grabow D et al (2010) Social outcomes of long-term survivors of adolescent cancer. Psychooncology 19:1277–1284PubMedCrossRef
Metadata
Title
Quality of life in long-term survivors following treatment for Hodgkin's disease during childhood and adolescence in the German multicentre studies between 1978 and 2002
Authors
Gabriele Calaminus
Wolfgang Dörffel
Katja Baust
Carmen Teske
Marianne Riepenhausen
Jürgen Brämswig
Hans-Henning Flechtner
Susanne Singer
Andreas Hinz
Günther Schellong
Publication date
01-06-2014
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 6/2014
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-013-2114-y

Other articles of this Issue 6/2014

Supportive Care in Cancer 6/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine